WuXi Biologics (Cayman) Inc.
SEHK-2269
Company Overview
WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the People's Republic of China, North America, Europe, and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine CDMO and related business; and material supplier activities. WuXi Biologics (Cayman) Inc. has strategic partnership with ImmuneOncia Therapeutics, Legochem Biosciences Inc, Worg Pharma, OncoC4, and Exelixis Inc. The company was incorporated in 2014 and is headquartered in Wuxi, China.
Name
WuXi Biologics (Cayman) Inc.
CEO
Dr. Zhisheng Chen
Website
www.wuxibiologics.com
Sector
Life Sciences Tools and Services
Year Founded
2014
Profile
Market Cap
HK$46.89B
EV
HK$45.84B
Shares Out
4,135.18M
Revenue
CN¥17.12B
Employees
12,435
Margins
Gross
38.66%
EBITDA
26.78%
Operating
20.16%
Pre-Tax
21.34%
Net
15.38%
FCF
3.65%
Returns (5Yr Avg)
ROA
7.7%
ROTA
10.55%
ROE
10.33%
ROCE
8.87%
ROIC
9.17%
Valuation (TTM)
P/E
—
P/B
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
EV/Gross Profit
—
Valuation (NTM)
Price Target
HK$19.24
P/E
—
PEG
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
Financial Health
Cash
CN¥9,528.68M
Net Debt
-CN¥4,961.48M
Debt/Equity
0.1
EBIT/Interest
23.35
Growth (CAGR)
Rev 3Yr
28.46%
Rev 5Yr
40.85%
Rev 10Yr
—
Dil EPS 3Yr
-2.26%
Dil EPS 5Yr
23.4%
Dil EPS 10Yr
—
Rev Fwd 2Yr
8.85%
EBITDA Fwd 2Yr
-0.02%
EPS Fwd 2Yr
1.38%
EPS LT Growth Est
8.57%
Dividends
Yield
—
Payout
—
DPS
—
DPS Growth 3Yr
—
DPS Growth 5Yr
—
DPS Growth 10Yr
—
DPS Growth Fwd 2Yr
—